Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG
Abstract
Progress in studying the androgen receptor (AR), the primary drug target in prostate cancer, has been hampered by challenges in expressing and purifying active multidomain AR for use in cell-free biochemical reconstitution assays. Here we successfully express full-length and truncated AR variants and demonstrate that the oncogenic ETS protein ERG, responsible for half of all prostate cancers, enhances the ability of AR to bind DNA through direct interaction with AR. In addition to providing a biochemical system to evaluate AR activity on different DNA templates, our findings provide insight into why ERG-positive prostate cancers have an expanded AR cistrome.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 27, 2020
- Source ID
- 10.1073/pnas.1922159117
Entities
People
- Albert Antar
- Charles Sawyers
- Elizabeth A. Hoover
- Elizabeth V Wasmuth
- Sebastian Klinge
- Yu Chen
Organizations
- Howard Hughes Medical Institute
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- The Rockefeller University
- United States Department of Defense